Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Heron securities between October 31, 2018 and April 30, 2019, inclusive.
NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc. (“Heron” or the “Company”) (NASDAQ: HRTX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Heron securities between October 31, 2018 and April 30, 2019, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/hrtx.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (2) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (3) as a result, Heron’s public statements were materially false and misleading at all relevant times.
On May 1, 2019, Heron announced receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) on April 30, 2019 regarding Heron’s New Drug Application (“NDA”) for HTX-011 for the management of postoperative pain. Heron advised investors that "[t]he CRL stated that the FDA is unable to approve the NDA in its present form based on the need for additional [Chemistry, Manufacturing, and Controls] and non-clinical information.” On this news, Heron’s stock price fell $3.93 per share, or 18.13%, to close at $17.75 per share on May 1, 2019.
If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/hrtx. or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Heron you have until August 5, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/final-deadlinehrtx-heron-therapeutics-inc---bronstein-gewirtz--grossman-llc-reminds-investors-of-class-action-and-lead-plaintiff-deadline-august-5-2019-300893916.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Company Codes: NASDAQ-SMALL:HRTX
